Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%

--Update on Ongoing Phase 1b/2 VERU -111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant Prostate Cancer-- -- VERU -111 Has Promising Signs of Progression Free Survival--               

December 12th, 2019|